650624-43-4

Basic information

• Product Name: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-
• CAS NO: 650624-43-4
• Molecular Formula: C23H35N3O8
• Molecular Weight: 481.546
• Mol File: 650624-43-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-(650624-43-4)
• EPA Substance Registry System: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-(650624-43-4)

Safety Data

• Hazardous Substances Data: 650624-43-4(Hazardous Substances Data)

Usage

General Description

L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl- is a chemical compound consisting of the amino acids leucine, tyrosine, and serine. It is commonly used in the synthesis of peptides and proteins, as well as in pharmaceutical research and development. L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl- is known for its ability to enhance muscle protein synthesis and promote muscle growth, making it a popular ingredient in sports supplements and fitness products. Additionally, it has potential therapeutic applications in the treatment of diseases related to protein metabolism and muscle wasting. Overall, L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl- has diverse and significant roles in the fields of biochemistry, pharmacology, and sports nutrition.

Upstream product

• 85328-90-1 (S)-2-((S)-2-tert-butoxycarbonylamino-3-hydroxypropanoylamino)-4-methylpentanoic acid methyl ester 
• 75816-57-8 Ser-Leu-OMe hydrochloridel 
• 7517-19-3 methyl (L)-leucinate hydrochloride 

Relevant articles and documents

The synthesis, distribution, and anti-hepatic cancer activity of YSL

(I) HCl/CH3OH; (II) DCC/HOBt/NMM with corresponding carboxyl component; (III) HCl/CH3CO2C2H5 (6 mol/L); (IV) NaOH/H2O/CH3OH; (V) 3H2 and 10% Pd/C. YSL was prepared stepwise from C terminal to N terminal with the side chain un-protective amino acids, Boc-Leu-OMe, Boc-Ser-OH, and Boc-Tyr-OH, as the starting materials in 39.5% total yield (31.2 g/per batch). With the side chain un-protective Boc-(3,5-dibromo)-Tyr-OH and HClA·Ser-Leu-OMe as the starting materials (3,5-3H-Tyr)-Ser-Leu-OH was obtained in 29% yield. The determination of radioactive quantity in the urine and feces indicated that even after the administration for 130 h only 8.4% (5.35% in urine and 3.05% in feces) of total radioactive quantity from the metabolite of [3,5-3H-Tyr]-Ser-Leu-OH were monitored. The distribution study revealed the relative accumulation level of the individual tissue was arranged in the sequence of spleen > liver > kidney > lung > heart > muscle > brain. Selecting hepatic cancer as the target YSL significantly increased the survival time of H22 tumor cells implanted mice.